Docmode Health (DHTL)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarterly sales of ₹18 Cr are higher than the entire ₹14 Cr market cap, indicating revenue is being generated.
• Profit growth of +82.69% shows some improvement, albeit from a negligible base.
• Piotroski F-Score of 5/9 is not outright distressed; current price is above the 52-week low of ₹31.60.
• Small market cap and low price-to-sales could attract speculative interest if fundamentals stabilize.

Concerns

• No real profitability: P/E is 0.00, latest quarter net profit is ₹-0 Cr, and ROCE is -0.29%.
• Sales growth is negative at -12.59%, showing a shrinking top line.
• Book value and debt/equity are N/A, so no margin of safety can be calculated.
• Promoter holding of only 30.86% and zero dividend raise governance and return concerns for a microcap.

AI Analysis

At ₹42, Docmode Health carries a market cap of just ₹14 crore. My first rule: never invest in something I can't value. Here the book value is unavailable, debt/equity is unavailable, and P/E is effectively meaningless because the latest quarter's net profit is zero. A business that earns nothing cannot justify a purchase on earnings power. Sales declined 12.59% year-over-year, and ROCE is -0.29%. The 82.69% profit growth looks impressive but starts from a negligible base; it is not evidence of a durable franchise. E-learning can be a decent business, but this is not a quality compounder. There is no evident moat, no dividend, and no meaningful return on capital. Promoter holding at 30.86% is okay, but for a microcap it is not high enough to convince me owners have large skin in the game; combined with insufficient data, it raises governance doubts. The positive: quarterly sales of ₹18 crore dwarf the ₹14 crore market cap, so the company is generating revenue. Yet profitability is missing. Piotroski score of 5 out of 9 is mediocre, not a green light. Current price is well below the 52-week high of ₹125.20, but a falling stock is not automatic bargain. Without book value or debt data, I cannot compute a margin of safety. I would classify this as a speculative turnaround candidate—to be watched, not bought. Intelligent investing requires facts; here there are too few. I'll pass until earnings, balance sheet, and cash flow become transparent.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer